Canadian and Australian prostate cancer researchers have discovered a key piece in the genetic puzzle of why men born with a BRCA2 mutation may develop aggressive localized cancers that resist treatment and become lethal for up to 50 per cent of patients within five years.
The findings, published in Nature Communications, show that BRCA2-associated tumours are already pre-set to be aggressive, even before treatment. This is because the genes normally involved in regulating cell growth and division are abnormal in the BRCA2-associated cancers right from the get-go and therefore are resistant to therapy right up front, says co-principal investigator Dr. Robert Bristow, clinician-scientist at Princess Margaret Cancer Centre, University Health Network. He talks about the research at https://youtu.be/dXlntpaWtaI
In the Nature Communications study, Dr. Bristow and co-principal investigators Dr. Paul Boutros at the Ontario Institute for Cancer Research, and Prof. Gail Risbridger at Monash University, Melbourne, Australia, compared 15 patients with BRCA2-inherited prostate cancer with 500 prostate cancer patients from the general population with non-inherited (“sporadic”) prostate cancer. In the related study of 500 tumours from Canadian men with non-inherited prostate cancer also published today, in Nature, Drs. Bristow and Boutros analyses led to the discovery of a new genetic fingerprint that identifies when curable disease may turn aggressive.
Although BRCA2-inherited disease affects less than two per cent of men with prostate cancer, Dr. Bristow says the research sets the stage to rethink ways to use other drugs differently to personalize treatment for more men.
“The pathways that we discovered to be abnormal in the localized BRCA2-associated cancers are usually only found in general population cancers when they become resistant to hormone therapy and spread through the body,” says Dr. Bristow.
“These include pathways related to the repair of DNA damage, cell division, the receptor for the male hormone testosterone and cell-to-cell signaling.
“We now know need to explore the use of novel therapies to offset the BRCA2-associated aggressiveness earlier on in the treatment of these men and improve survival in an otherwise lethal tumour,” he says. “This might include different types of chemotherapy or the use of molecular-targeted drugs that specifically target the changes associated with BRCA2 mutation.”
“This is an exciting time in prostate cancer research in which the genetics of individual men and their cancers are beginning to dictate precise and customized treatment,” he adds. “It is an example of the power of international collaboration and team science to crack the genetic code even in rarest of tumours.”
Drs. Bristow and Boutros also co-lead the Canadian Prostate Cancer Genome Network (CPC-GENE) Sequencing Project, a world-leading prostate sequencing program. Both are affiliated with University of Toronto where Dr. Bristow is a Professor in the Departments of Radiation Oncology and Medical Biophysics, and Dr. Boutros is an Assistant Professor, Department of Medical Biophysics.
Funding was provided by the Movember Foundation through Prostate Cancer Canada, the Ontario Institute for Cancer Research, CPC-GENE, and The Princess Margaret Cancer Foundation.
About Princess Margaret Cancer Centre, University Health Network
The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute and the Michener Institute for Education; all affiliated with the University of Toronto. For more information, go to www.theprincessmargaret.ca or www.uhn.ca.